Rx Bandz gets new funding for MiniJect FDA filing

Rx Bandz closed another advance from Leonid Capital Partners to help manufacture its MiniJect auto-injector platform and prepare an FDA submission expected in late 2026. The funding extends runway for military and civilian drug-delivery programs tied to battlefield pain management and other emergency uses.

Why it matters: - The advance gives Rx Bandz non-dilutive capital for manufacturing and regulatory work on MiniJect, reducing pressure on the company’s current equity raise. - The funding supports a platform meant to move from military R&D into broader commercial and emergency-medicine use. - Rx Bandz is aiming to turn government-funded development into an FDA-ready product that could attract pharmaceutical partners.

What happened: - Rx Bandz closed a third-tranche advance with Leonid Capital Partners on July 9, 2026. - Financial terms were not disclosed. - The advance builds on Leonid’s initial 2024 credit facility. - The money will support manufacturing of the proprietary MiniJect auto-injector platform ahead of FDA submission. - Rx Bandz expects to submit to the FDA in late 2026.

The details: - Rx Bandz says it has more than a dozen U.S. military R&D contracts for next-generation drug delivery technologies. - The company says it has received more than $30 million in U.S. military R&D contracts since founding. - Rx Bandz’s ketamine and hydromorphone auto-injector programs have advanced to Phase III SBIR contracts with the U.S. Air Force’s 711th Human Performance Wing Advanced Development. - The company plans to use the proceeds to keep developing therapeutics focused on battlefield pain management. - MiniJect formulations also have commercial applications in postpartum hemorrhage, antibiotic treatment and major depressive disorder. - The MiniJect platform is designed to deliver small molecules, biologics and other highly viscous therapeutics. - Rx Bandz is engaged in licensing discussions with multiple pharmaceutical companies. - The company is working on its Device Master File and on manufacturing validation, reliability testing and human factors studies for FDA submission. - The company says the current advance extends its operational runway through FDA submission while preserving the option of its current $8 million Series A round. - Rx Bandz also says financing against its government contract portfolio is a capital-efficient way to convert program execution into working capital. - Leonid Capital Partners provides venture debt financing backed by government contracts for companies working on national security and other strategic government priorities.

Between the lines: - The transaction signals that Leonid sees lower risk in Rx Bandz’s government-backed contract base than in a purely venture-funded medtech story. - MiniJect’s dual-use framing matters because it broadens the path to revenue beyond defense customers. - The FDA filing is the key near-term catalyst, since it could make MiniJect more credible to drugmakers looking for delivery platforms.

What's next: - Rx Bandz plans to finish the regulatory package and submit MiniJect to the FDA in late 2026. - The company will keep manufacturing and validation work moving as it prepares for the filing. - Rx Bandz expects continued talks with pharmaceutical partners as the platform moves closer to review. - Learn more about Rx Bandz - Learn more about Leonid Capital Partners - Watch the company video